Bench to Bedside

Pharmaceuticals have transformed modern medicine. Penicillin, chemotherapy, and mRNA vaccines have saved millions of lives, yet the industry is often misunderstood, seen as a mix of scientific brilliance and corporate complexity. In Bench to Bedside: The Business of Drug Development, Fraser Gibson takes readers inside this world, tracing the journey of a new therapy from the laboratory bench to the patient's bedside. Along the way, he explains why developing a single drug can take over a decade, cost billions, and still end in failure, and why so many promising discoveries never make it to market. Readers will discover: ¿ Why drug development is so costly, lengthy, and uncertain ¿ The roles of scientists, regulators, pharmaceutical companies, and patients in bringing therapies to life ¿ How digital health tools and artificial intelligence are changing the research landscape ¿ What the future of innovation might mean for medicine and society Bench to Bedside offers a grounded and accessible look at one of the world's most vital and often misunderstood industries. It reminds readers that behind every therapy lies not just data and dollars, but people, innovation, and the ongoing pursuit of better health for all.